Compare BMEZ & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMEZ | GOSS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.9M | 796.2M |
| IPO Year | N/A | 2019 |
| Metric | BMEZ | GOSS |
|---|---|---|
| Price | $15.38 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 391.3K | ★ 5.0M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | ★ $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.93 | $0.76 |
| 52 Week High | $16.95 | $3.87 |
| Indicator | BMEZ | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 38.33 |
| Support Level | $15.11 | $2.44 |
| Resistance Level | $15.55 | $2.69 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 67.44 | 17.00 |
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.